On April 6, 2022 Carina reported that has had five abstracts accepted for poster presentations at the AACR (Free AACR Whitepaper) Annual Meeting which will take place from April 8 to April 13 (Press release, Carina Biotech, APR 6, 2022, View Source [SID1234611488]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentations come after Carina’s recent submission of a pre-IND package to the FDA for Carina’s LGR5 CAR-T cell for the treatment of patients with advanced colorectal cancer.

HIGHLIGHTS

Five conference abstracts will be presented as poster presentations at AACR (Free AACR Whitepaper) in the immuno-oncology and preclinical immunotherapy sessions
Four presentations describe preclinical data from Carina’s LGR5-targeted CAR-T cell program, one poster will describe preclinical data from Carina’s ADAM-10 CAR-T program
With its LGR5 CAR-T, Carina is progressing towards a first-in-human clinical trial in patients with advanced colorectal cancer
Colorectal cancer is the third most commonly diagnosed cancer in Australia and in the United States, and the second leading cause of cancer death in Australia
Carina’s five presentations and their authors are:

Session OPO.CL06.01 – Immuno-oncology
(April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
5183 – LGR5 CAR-T cells: A novel potential treatment against high grade serous ovarian cancer authors B Wanqi Wang, Veronika Bandara, Noor Lokman, Silvana Napoli, Batjargal Gundsambuu, Martin Oehler, Simon Barry, Carmela Ricciardelli
Session OPO.IM02.01 – Preclinical immunotherapy
(April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
5575 – Pre-clinical validation of a LGR5-targeting CAR-T against colorectal cancer authors Veronika Bandara, Stuart Mills, Emma Thompson, Lih Tan, Batjargal Gundsambuu, Silvana Napoli, Jade Foeng, Dylan McPeake, Justin Coombs, Allison Cowin, Claudine Bonder, Timothy Sadlon, Shaun McColl, Simon Barry
Session OPO.IM02.01 – Preclinical immunotherapy
(April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
5574 – In vivo characterisation of a novel CAR-T cell therapy directed towards LGR5 for the treatment of colorectal cancer authors Dylan McPeake, Timona Tyllis, Jade Foeng, Veronika Bandara, Caitlin Abbott, Batjargal Gundsambuu, Elaheh Rohani-Rad, Silvana Napoli, Timothy Sadlon, Simon Barry, Shaun McColl
Session OPO.CL06.01 – Immuno-oncology
(April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
5184 – Real-time cytotoxicity assays as a pre-clinical screening tool for LGR5-targeting CAR-T cells for treatment of solid tumors authors Emma Thompson, Veronika Bandara, Timothy Sadlon, Batjargal Gundsambuu, Lih Yin Tan, Carmela Ricciardelli, Simon Barry, Claudine Bonder
Session OPO.IM02.01 – Preclinical immunotherapy
(April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
5505 – ADAM10-targeting CAR-T cells inhibit colon cancer cell growth in vivo authors Elaheh Rohani Rad, Jade Foeng, Dylan McPeake, Timona Tyllis, Caitlin Abbott, Veronika Bandara, Silvana Napoli, Batjargal Gundambuu, Timothy Sadlon, Simon Barry, Shaun McColl

About LGR5
LGR5 is a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. In colorectal cancer patients, LGR5+ expression has been correlated with a particularly poor prognosis.

Cancer stem cells are a small sub-population of cells within a tumour with the ability to self-renew, differentiate into the many cell types of a tumour, initiate new tumours, and resist chemotherapy and radiotherapy (leading to relapses).

By targeting cancer stem cells, it is hoped that this therapy will reduce the tumour’s ability to generate new cancer cells, resulting in durable tumour suppression and preventing the relapses that are very common in patients with colorectal cancer.

Carina’s pre-clinical studies of the LGR5-targeted CAR-T cell have shown highly promising results with complete tumour regression and no tumour recurrence. They have also demonstrated impressive tumour access and prolonged CAR-T cell survival.